Laminin alpha2 chain-deficient congenital muscular dystrophy: variable epitope expression in severe and mild cases.
OBJECTIVE
To characterize the expression of distinct fragments of laminin alpha2 chain in patients with partial laminin alpha2 chain deficiency and variable clinical severity.


BACKGROUND
Deficiency of laminin alpha2 chain caused by mutations of the LAMA2 gene on chromosome 6q2 account for approximately 50% of cases of congenital muscular dystrophy (CMD) in white patients. The complete absence of laminin alpha2 is usually associated with a severe phenotype affecting skeletal muscle and the peripheral and central nervous systems.


METHODS
Quantitative assessment of immunofluorescence to study the expression of C- and N-terminal portions of laminin alpha2 chain in five patients with partial laminin alpha2 chain deficiency and variable phenotype. All five patients showed abnormal T2 signal on brain MRI.


RESULTS
Immunohistochemistry of muscle specimens showed preserved or minimally reduced expression of the C-terminal region of the laminin alpha2 chain (67 to 74%), but a marked reduction of the N-terminal region in four patients (13 to 19%). One patient with a mild phenotype had a partial reduction (45%) of the C-terminal and the N-terminal (51%) portions of the laminin alpha2 chain. Two patients were unable to walk or sit, although the C-terminal portion of the laminin alpha2 chain was expressed at significant levels (67 to 74%). In contrast, two patients with a similar expression of the C-terminus (67 to 70%) had a milder phenotype and became ambulatory. It was impossible to predict the phenotypes in these four patients with a strong expression of the C-terminus and with low levels of the N-terminus based on the amount of protein expressed. In addition, the laminin beta2 chain was moderately reduced (54 to 75%) in all patients with laminin alpha2 chain deficiency. A strong correlation between the amount of the C-terminus but not for the N-terminus and laminin beta2 reduction could be observed.


CONCLUSIONS
N-terminal antibodies to the laminin alpha2 chain provide a more precise immunohistochemical detection of partially laminin alpha2 chain-deficient CMD. The secondary reduction of laminin beta2 chain may better define laminin alpha2 chain-deficient CMD. More data are needed to predict which portions of C-terminus and midrod region of the laminin alpha2 chain result in a semifunctional protein and a milder phenotype.
Cohn
R D
RD
Department of Pediatrics, University of Essen, Germany.
Herrmann
R
R
Sorokin
L
L
Wewer
U M
UM
Voit
T
T
D000328:Adult; D000906:Antibodies; D001485:Basement Membrane / Q000737:chemistry / Q000276:immunology; D002675:Child, Preschool; D000939:Epitopes / Q000032:analysis; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D007231:Infant, Newborn; D007797:Laminin / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D009136:Muscular Dystrophies / Q000151:congenital* / Q000235:genetics*; D010641:Phenotype; D017434:Protein Structure, Tertiary
D000906:Antibodies; D000939:Epitopes; D007797:Laminin; C102645:laminin alpha 2; C058783:laminin beta2